我們已在上線! 進一步了解
BLU

BELLUS Health Inc.

已下市

BLU已於2023年6月28日下市。

 

關於: BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, a P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

員工: 74

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於BLU的最新新聞文章。

價格圖表採用Lightweight Charts™實作